RxDoctor Payments Data

Christopher Horn, DO

Family Medicine · Rockaway, NJNPI 1821095605

Payments from drug & device makers

$8,911in general payments, 2019–2025

Across 553 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$990
  • AstraZeneca$987
  • AbbVie$916
  • Pfizer$845
  • Boehringer Ingelheim$820
  • Lilly USA, LLC$734
  • plus $4K from 36 others

What the payments were for

  • Food & beverage$8,905100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,911 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.

See all family medicine providers in New Jersey

Medicare billing

Part B allowed, 2024
$186,105
Medicare patients
342
Services billed
4,148

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin70$75,197
MounjaroTirzepatide51$55,789
OzempicSemaglutide25$35,551
TrulicityDulaglutide29$29,593
Trelegy ElliptaFluticasone/Umeclidin/Vilanter30$26,078
Janumet XrSitagliptin Phos/Metformin Hcl23$21,156
EliquisApixaban16$16,418
JanuviaSitagliptin Phosphate18$15,999
XareltoRivaroxaban13$14,908
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$11,349
Rosuvastatin Calcium304$4,150
Valsartan118$3,752
Levothyroxine Sodium303$3,063
Atorvastatin Calcium355$2,917
CholestyramineCholestyramine (With Sugar)23$2,405

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$734$85,38280 claims
Boehringer IngelheimJardiance$820$75,19770 claims
MerckJanumet Xr, Januvia$275$37,15541 claims
Novo NordiskOzempic$990$35,55125 claims
GSKTrelegy Ellipta$473$26,07830 claims
PfizerEliquis$845$16,41816 claims
Johnson & JohnsonXarelto$263$14,90813 claims
AstraZenecaBreztri Aerosphere$987$11,34917 claims
AbbVieSynthroid$916$1,56624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.

Other family medicine in Rockaway

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →